Layoffs
The Orphazyme board of directors decided to cut 50% of its current global staff count after carefully considering its financial state.
Gilead Sciences is letting go of 114 employees following an underwhelming response to the results reaped so far from its $21 billion acquisition of Immunomedics in 2020.
Shares of Adaptive are climbing this morning after the company announced a reorganization of priorities to spur future growth, including a workforce reduction of approximately 12%.
After months of speculation about looming layoffs, Biogen is handing out pink slips in order to save about $500 million.
Gemini will undertake a corporate restructuring that will see a drastic 80% of its workforce laid off.
The agreement would have created a spin-off gene therapy company and merged it with ARYA IV to create a new, publicly-traded entity called Caritas Therapies.
In addition to massive layoffs – around 60% of its workforce – Yumanity also said it is considering “strategic alternatives” to its financial woes, including the possibility of selling or merging.
On Thursday, Unity Biotechnology announced that it is cutting 50% of its workforce, mainly in the research department.
As part of a company-wide workforce reduction, it will cut its employee headcount by at least 25% by the end of the year, and 50% of its senior management team are leaving the company.
The job cuts were announced as part of an organizational streamlining initiative that will refocus resources toward the company’s highest-value activities.
PRESS RELEASES
